Hematology Reports (Dec 2011)

Therapy related acute myeloid leukemia with t(10:16): a rare entity

  • Guldeep K. Uppal,
  • John Leighton,
  • Deline Da Costa,
  • Andrew Czulewicz,
  • Irma E. Palazzo

DOI
https://doi.org/10.4081/hr.2011.e23
Journal volume & issue
Vol. 3, no. 3
pp. e23 – e23

Abstract

Read online

Treatment related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) are well known complications after chemotherapy for various hematologic and non-hematologic malignancies. Alkylating agents and Topoisomerase inhibitors are most widely studied in this regard. There is growing concern about occurrence of t-MDS, t- MDS/AML and t-AML in patients of CLL treated with nucleoside analogues especially in combination with alkylating agents. Exact incidence and pathogenesis of nucleoside analogue related MDS/AML is not clear at this time. We hereby report a case of t-AML in a patient treated with Fludarabine, Cyclophosphamide and Rituximab (FCR) for CLL. The cytogenetic studies revealed a unique translocation t (10:16), that has been reported in very few cases of therapy related AML and pediatric AML.

Keywords